Zonisamide discontinuation due to psychiatric and cognitive adverse events: A case-control study

Neurology

Volumn 75, Issue 6, 2010, Pages 513-518

  White, J R ^a,b   Walczak, T S ^a,b   Marino, S E ^b,c   Beniak, T E ^a   Leppik, I E ^a,b   Birnbaum, A K ^b,c  

^a MINCEP Epilepsy Care   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OXCARBAZEPINE; VALPROIC ACID; ZONISAMIDE; ISOXAZOLE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BEHAVIOR DISORDER; CASE CONTROL STUDY; CLINICAL PRACTICE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG OVERDOSE; DRUG WITHDRAWAL; EPILEPSY; FEMALE; GENERALIZED EPILEPSY; HUMAN; IRRITABILITY; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEMORY DISORDER; MENTAL CONCENTRATION; MENTAL DISEASE; MONOTHERAPY; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SUICIDE ATTEMPT; TREATMENT DURATION; CHEMICALLY INDUCED; COGNITION DISORDERS; COMPARATIVE STUDY; MENTAL DISORDERS; MIDDLE AGED; PSYCHOLOGY; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; ANTICONVULSANTS; CASE-CONTROL STUDIES; COGNITION DISORDERS; EPILEPSY; FEMALE; HUMANS; ISOXAZOLES; MALE; MENTAL DISORDERS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 77955451598     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181eccfb5     Document Type: Article

References (25)

1. Faught E, Ayala R, Montouris GG, Leppik IE, Zoni-samide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;57:1774-1779.
2. Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007;30:230-240.
3. Murata M, Hasegawa K, Kanazawa I, The Japan Zoni-samide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007;68:45-50.
4. Leppik IE. Practical prescribing and long-term efficacy and safety of zonisamide. Epilepsy Res 2006;68(suppl 2):S17-S24.
5. Charles CL, Stoesz L, Tollefson G. Zonisamide induced mania. Psychosomatics 1990;2:214-217.
6. Arif H, Buchsbaum R, Weintraub D, Pierro J, Resor SR, Hirsch LJ. Patient-reported cognitive side effects of anti-epileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav 2009;14: 202-209.
7. Mago R, Huege S, Ahuja N, Kunkel EJS. Zonisamide-induced suicidal ideation. Psychosomatics 2006;47:68-69.
8. Weintraub D, Buchsbaum R, Resor SR, Hirsch LJ. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2007;10: 105-110.
9. Miyamoto T, Kohsaka M, Koyama T. Psychotic episodes during zonisamide treatment. Seizure 2000;9:65-70.
10. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Translational Sciences, Office of Biosta-tistics. Statistical review and evaluation: antiepileptic drugs and suicidality. Available at: www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationfor patientsandProviders/UCM192556.pdf. Accessed January 11 2010.
11. American Epilepsy Society. Statement from the American Epilepsy Society in response to the December 16, 2008, FDA announcement about suicide warnings that will now be required on all antiepileptic drugs. Available at: www. aesnet.org/index.cfm?objectid=46c6df2a-e7ff-of41-244a 324bc56f51a1. Accessed February 1, 2009.
12. Park SP, Hwang YH, Lee HW, Suh CK, Kwon SH, Lee BI. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav 2008; 12:102-108.
13. Berent S, Sackellares JC, Giordani B, Wagner JG, Dono-frio PD, Abou-Khalil B. Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 1987;28: 61-67.
14. Ojemann LM, Ojemann GA, Dodrill CB, Crawford CA, Holmes MD, Dudley DL. Language disturbances as side effects of topiramate and zonisamide therapy. Epilepsy Behav 2001;2:579-584.
15. Duval V, Karisson M. Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharm Res 2004;19: 1835-1840.
16. Kanner AM. Can antiepileptic drugs unmask a susceptibility to psychiatric disorders? Nat Clin Pract Neurol 2009;5: 132-133.
17. Mula M, Trimble MR, Yuen A, Liu RSN, Sander JWAS. Psychiatric adverse events during levetiracetam therapy. Neurology 2003;61:704-706. (Pubitemid 37082613)
18. White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects: a case control study. Neurology 2003;61:1218-1221.
19. Besag FMC. Behavioral effects of the new anticonvulsants. Drug Saf 2001;24:513-536.
20. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995;22: 193-205.
21. Okada M, Hirano T, Kawata Y, et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res 1999;34:187-197.
22. Wilensky AJ, Friel PN, Ojemann LM, Dodrill CB, Mc-Cormick, Levy RH. Zonisamide in epilepsy: a pilot study. Epilepsia 1985;26:212-220.
23. Zaccara G, Specchio LM. Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat 2009;5:249-259.
24. Mula M, Trimble MR, Sander JW. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia 2007;48:2322-2326.
25. Tatum WO, French JA, Faught E, et al. Postmarketing experience with topiramate and cognition. Epilepsia 2001; 42:1134-1140.